GAUSH MEDITECH LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.5 HKD | -2.40% |
|
-7.14% | -48.41% |
| May. 02 | Gaush Meditech Swings to Profit in 2023 | MT |
| Apr. 23 | Gaush Meditech Ltd Announces Change in Joint Company Secretary | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 | 1.41B 195M 1.52B | Sales 2024 * | 1.61B 223M 1.74B | Capitalization | 2.67B 369M 2.89B |
|---|---|---|---|---|---|
| Net income 2023 | 174M 24.09M 188M | Net income 2024 * | 239M 33.08M 258M | EV / Sales 2023 | 3.62 x |
| Net cash position 2023 * | 280M 38.81M 303M | Net cash position 2024 * | 161M 22.32M 174M | EV / Sales 2024 * | 1.56 x |
| P/E ratio 2023 |
29.4
x | P/E ratio 2024 * |
11.1
x | Employees | 869 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 25.63% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.40% | ||
| 1 week | -7.14% | ||
| Current month | -2.21% | ||
| 1 month | +6.91% | ||
| 3 months | -32.76% | ||
| 6 months | -49.15% | ||
| Current year | -48.41% |
1 week
19.30
20.80
1 month
15.2021.80
Current year
15.2042.05
1 year
15.2049.50
3 years
15.2056.10
5 years
15.2056.10
10 years
15.2056.10
| Managers | Title | Age | Since |
|---|---|---|---|
Xin Wei Liu
CEO | Chief Executive Officer | 42 | 18-11-30 |
Tie Ta Gao
FOU | Founder | 60 | 17-10-31 |
Wen Qi Li
DFI | Director of Finance/CFO | 50 | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guo Wei Wang
BRD | Director/Board Member | 63 | 17-12-28 |
Fan Shing Chan
BRD | Director/Board Member | 47 | 22-11-10 |
Tie Ta Gao
FOU | Founder | 60 | 17-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 19.5 | -2.40% | 110,900 |
| 24-05-09 | 19.98 | +2.36% | 87,600 |
| 24-05-08 | 19.52 | 0.00% | 86,700 |
| 24-05-07 | 19.52 | -4.08% | 106,300 |
| 24-05-06 | 20.35 | -1.21% | 100,600 |
Delayed Quote Hong Kong S.E., May 10, 2024 at 04:08 am EDT
More quotes
Gaush Meditech Ltd is a China-based company mainly engaged in ophthalmology medical business. The Company operates in four segments. Proprietary Products segment develops and produces surgical equipment and related supporting software, intra optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables. Distribution segment sells brand ophthalmic medical devices and consumables. Technical Services segment provides warranty service, maintenance service and consumables related to after-sales service. Others segment is mainly engaged in equipment leasing business and intellectual property agency services. The Company's products are widely used in the examination, treatment and correction of ophthalmic subspecialty diseases such as fundus disease, cataract, glaucoma, refraction, optometry, ocular surface, and children's ophthalmology.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
18.03
CNY
Average target price
27.79
CNY
Spread / Average Target
+54.13%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -48.41% | 369M | |
| -0.44% | 1.45B | |
| -3.32% | 1.43B | |
| -5.79% | 1.21B | |
| -14.59% | 899M | |
| +1.72% | 480M | |
| +3.85% | 440M | |
| -19.75% | 356M | |
| -2.93% | 213M | |
| -28.04% | 209M |
- Stock Market
- Equities
- 2407 Stock